Coenzyme Q10 | Cleveland Clinic Laboratories

Coenzyme Q10 Print

Test Mnemonic

COEQ10

CPT Codes

82542 - QTY (1)

Performing Laboratory

Mayo Clinic Dpt of Lab Med & Pathology

Specimen Requirements

Volume	Type	Container	Collect Temperature	Transport Temperature	Special Instructions
0.5 mL	Plasma	Sodium or Lithium heparin (Green)	N/A	Place specimen on ice after draw.	Remove plasma from cells within 3 hours and freeze. Collect Monday - Thursday only. Patient should fast for 8 hours pior to collection. Transport frozen.

Minimum Specimen Requirements

Volume	Type	Container	Collect Temperature	Transport Temperature	Special Instructions
0.3 mL

Stability

Environmental Condition	Description
Frozen	14 days
Refrigerated	8 hours
Ambient	Unacceptable

Days Performed

Varies

Turnaround Time

4 - 8 days

Methodology

Name	Description
High Performance Liquid Chromatography with Electrochemical Detection

Reference Range

Coenz Q10 % Reduced
Sex	Age From	Age To	Type	Range	Range Unit
	Years	17 Years	Normal	93 - 100	%
	18 Years	99 Years	Normal	92 - 98	%
Coenz Q10 Reduced
Sex	Age From	Age To	Type	Range	Range Unit
	Years	17 Years	Normal	320 - 1376	mcg/L
	18 Years	99 Years	Normal	415 - 1480	mcg/L
Coenzyme Q10 Total
Sex	Age From	Age To	Type	Range	Range Unit
	Years	17 Years	Normal	320 - 1558	mcg/L
	18 Years	99 Years	Normal	433 - 1532	mcg/L

Special Info

Freeze plasma within 3 hours of collection. Failure to follow specimen handling guidelines may lead to false positive results. Hemolyzed, lipemic and grossly icteric specimens will be rejected.

Clinical Info

Potential indications for testing coenzyme Q10 status include: Suspected coenzyme Q10 deficiency secondary to inheritance or other mitochondrial disease, cardiomyopathy, neurodegenerative diseases (Parkinson's, Alzheimer's, muscular dystrophy, ALS), metabolic disease, malnutrition, presurgical screening for patient who have pre-existing coenzyme Q10 deficiency or who may have increased risk of ischemia-reperfusion injury, prior treatment with HMG-CoA reductase inhibitors ('statin' drugs) or other drugs which may lower coenzyme Q10 levels, gastrointestinal malabsorption, and assessment of coenzyme Q10 dosing adequacy.